Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells

Gynecologic Oncology

Volumn 113, Issue 2, 2009, Pages 270-276

  Takahashi, Akira ^a,b   Kato, Kiyoko ^a   Kuboyama, Ayumi ^a   Inoue, Takafumi ^a   Tanaka, Yoshihiro ^a   Kuhara, Aya ^a   Kinoshita, Katsuyuki ^b   Takeda, Satoru ^b   Wake, Norio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

cAMP; Ovarian cancer; Progesterone receptor; Senescence

Indexed keywords

CYCLIC AMP; PROGESTERONE RECEPTOR B; PROTEIN P21; PROTEIN P27; RAS PROTEIN; RETINOBLASTOMA PROTEIN;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENICITY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRAIN 3T3; CELL TRANSFORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENESCENCE; WESTERN BLOTTING;

ANIMALS; BUCLADESINE; CELL AGING; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MICE; NIH 3T3 CELLS; OVARIAN NEOPLASMS; RECEPTORS, PROGESTERONE; UP-REGULATION;

EID: 64149122242     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.032     Document Type: Article

References (37)

1. Luce T.L., Dow K.H., and Holcomb L. Early diagnosis key to epithelial ovarian cancer detection. Nurse Pract. 28 (2003) 41-47 [quiz 48-9]
2. Bell D.A. Ovarian surface epithelial-stromal tumors. Hum. Pathol. 22 (1991) 750-762
3. Scully R.E. Pathology of ovarian cancer precursors. J. Cell. Biochem., Suppl. 23 (1995) 208-218
4. Risch H.A. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol. Oncol. 63 (1996) 254-257
5. Riman T., Dickman P.W., Nilsson S., Correia N., Nordlinder H., Magnusson C.M., et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J. Natl. Cancer Inst. 94 (2002) 497-504
6. Ho S.M. Estrogen, progesterone and epithelial ovarian cancer. Reprod. Biol. Endocrinol. 1 (2003) 73
7. Hempling R.E., Piver M.S., Eltabbakh G.H., and Recio F.O. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am. J. Clin. Oncol. 21 (1998) 447-451
8. Akahira J., Inoue T., Suzuki T., Ito K., Konno R., Sato S., et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br. J. Cancer 83 (2000) 1488-1494
9. Munstedt K., Steen J., Knauf A.G., Buch T., von Georgi R., and Franke F.E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89 (2000) 1783-1791
10. Hornung R., Urs E., Serenella E., Edward W., Ursula S., Urs H., et al. Analysis of potential prognostic factors in 111 patients with ovarian cancer. Cancer Lett. 206 (2004) 97-106
11. Lee P., Rosen D.G., Zhu C., Silva E.G., and Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol. Oncol. 96 (2005) 671-677
12. Mukherjee K., Syed V., and Ho S.M. Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene 24 (2005) 4388-4400
13. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895
14. Jensen J. Effects of sex steroids on serum lipids and lipoproteins. Bailliere's Clin. Obstet. Gynaecol. 5 (1991) 867-887
15. Denner L.A., Weigel N.L., Maxwell B.L., Schrader W.T., and O'Malley B.W. Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250 (1990) 1740-1743
16. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
17. Sherr C.J., and Robert J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 313 (1999) 1501-1512
18. Edgar B.A. Orr-Weaver TL. Endoreplication cell cycles: more for less. Cell 105 (2001) 297-306
19. Grana X., and Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growthy suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11 (1995) 211-219
20. Kato K., Ueoka Y., Hachiya T., Nishida J., and Wake N. Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene 15 (1997) 3037-3046
21. Horiuchi S., Kato K., Suga S., Takahashi A., Ueoka Y., Arima T., et al. Expression of progesterone receptor B is associated with G0/G1 arrest of the cell cycle and growth inhibition in NIH3T3 cells. Exp. Cell Res. 305 (2005) 233-243
22. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9363-9367
23. Ramirez P.T., Gershenson D.M., Tortolero-Luna G., Ramondetta L.M., Fightmaster D., Wharton J.T., et al. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53. Gynecol. Oncol. 83 (2001) 543-548
24. Clemens J.W., Robker R.L., Kraus W.L., Katzenellenbogen B.S., and Richards J.S. Hormone induction of progesterone receptor (PR) messenger ribonucleic acid and activation of PR promoter regions in ovarian granulosa cells: evidence for a role of cyclic adenosine 3′,5′-monophosphate but not estradiol. Mol. Endocrinol. 12 (1998) 1201-1214
25. Serrano M., Lin A.W., McCurrach M.E., Beach D., and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88 (1997) 593-602
26. Zhu J., Woods D., McMahon M., and Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12 (1998) 2997-3007
27. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., and Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12 (1998) 3008-3019
28. Palmero I., Pantoja C., and Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 395 (1998) 125-126
29. Huttner A., Lei T., Fahlbusch R., Schrell W., and Adams E.F. Relationship between cAMP induced inhibition of human meningioma cell proliferation and autocrine secretion of interleukin-6. Life Sci. 58 (1996) 1323-1329
30. Kamiya Y., Kawaguchi M., Ito J., Fujii T., Sakuma N., and Fujinami T. Effect of cholera toxin and pertussis toxin on the growth of A431 cells: kinetics of cyclic AMP and inositol trisphosphate in toxin-treated cells. Horm. Metab. Res. 27 (1995) 137-140
31. Laskin D.L., Beavis A.J., Sirak A.A., O'Connell S.M., and Laskin J.D. Differentiation of U-937 histiocytic lymphoma cells towards mature neutrophilic granulocytes by dibutyryl cyclic adenosine-3′,5′-monophosphate. Cancer Res. 50 (1990) 20-25
32. Mohan S., and Baylink D.J. Evidence that the inhibition of TE85 human bone cell proliferation by agents which stimulate cAMP production may in part be mediated by changes in the IGF-II regulatory system. Growth. Regul. 1 (1991) 110-118
33. Ohmura E., Wakai K., Isozaki O., Murakami H., Onoda N., Emoto N., et al. Inhibition of human pancreatic cancer cell (MIA PaCa-2) growth by cholera toxin and 8-chloro-cAMP in vitro. Br. J. Cancer 67 (1993) 279-283
34. Kim S.N., Ahn Y.H., Kim S.G., Park S.D., Cho-Chung Y.S., and Hong S.H. 8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells. Int. J. Cancer 93 (2001) 33-41
35. Tortora G., Clair T., Katsaros D., Ally S., Colamonici O., Neckers L.M., et al. Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 2849-2852
36. Tortora G., Pepe S., Yokozaki H., Meissner S., and Cho-Chung Y.S. Cooperative effect of 8-Cl-cAMP and rhGM-CSF on the differentiation of HL-60 human leukemia cells. Biochem. Biophys. Res. Commun. 177 (1991) 1133-1140
37. Shaw T.J., Keszthelyi E.J., Tonary A.M., Cada M., and Vanderhyden B.C. Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Exp. Cell Res. 273 (2002) 95-106